Search results
Author(s):
Amarinder Bindra
,
Shelley A Hall
Added:
3 years ago
After a drought in viable new therapies for more than a decade, two new drugs for use in heart failure patients were approved by the US Food and Drug Administration (FDA) in 2015. These drugs represent two new classes of agents in the heart failure space: a combined angiotensin receptor-neprilysin inhibitor (ARNI) (sacubitril/valsartan; brand name Entresto®, Novartis) and a sinoatrial node…
View more
Author(s):
Larry A Allen
,
John S Rumsfeld
Added:
3 years ago
Hospital readmissions contribute significant clinical and economic burden to patients and payers.1 Nearly 20 % of Medicare patients are readmitted to the hospital within 30 days of discharge, with heart failure listed as the most common reason for readmission.2 Based on a more than twofold variation in institutional readmission rates adjusted for patient clinical characteristics,3 preventable…
View more
Author(s):
Nehal Dhaduk
,
Adib Chaus
,
David Williams
,
et al
Added:
1 week ago
Author(s):
G Michael Felker
,
Christopher B Granger
Added:
3 years ago
Chronic heart failure is common, disabling and deadly. It affects approximately five million people in the US and accounts for over one million hospitalizations annually. Despite continued improvements in heart failure therapy, mortality over five years is approximately 50%.This article summarizes significant recent developments in pharmacologic and device therapy for heart failure.
Angiotensin…
View more
Author(s):
Neal M Dixit
,
Shivani Shah
,
Boback Ziaeian
,
et al
Added:
2 years ago
Author(s):
G Michael Felker
,
Christopher B Granger
Added:
3 years ago
Chronic heart failure is common, disabling and deadly. It affects approximately five million people in the US and accounts for over one million hospitalizations annually.1 Despite continued improvements in heart failure therapy, mortality over five years is approximately 50%.2 This article summarizes significant recent developments in pharmacologic and device therapy for heart failure.
…
View more
Author(s):
Kelly H Schlendorf
,
Jared O’Leary
,
JoAnn Lindenfeld
Added:
3 years ago
Mitral regurgitation (MR) is common in industrialized countries, with a prevalence of about 2% in the general population and about 9% in people over 75 years old.1,2 MR is classified as primary/degenerative when it results from a structural abnormality of the valve apparatus, or secondary/functional when it results from a disturbance of ventricular or annular geometry and/or function that impairs…
View more
Author(s):
Matthew F Yuyun
,
Ghulam Muqtada Chaudhry
Added:
3 years ago
Cardiac pacing has evolved considerably over the years from its initial introduction as a lifesaving measure by asynchronous ventricular pacing. Pitfalls of ventricular-only pacing were recognized relatively early, which led to the introduction of atrioventricular (AV) synchronous pacing that was subjected to rigorous clinical studies.1 A meta-analysis of major pacing mode trials revealed that AV…
View more
Author(s):
Shanmugam Uthamalingam
,
James L Januzzi
Added:
3 years ago
Several cardiac biomarkers may aid in the diagnostic and prognostic evaluation of acute and chronic heart failure. In this article we discuss more novel and emerging applications of such established cardiac biomarkers in heart failure and review emerging data for several other promising markers.
Novel Applications of Established Cardiac Biomarkers—Natriuretic Peptides
B-type natriuretic peptide…
View more
Author(s):
Michael T Cain
,
Michael S Firstenberg
,
Joseph C Cleveland Jr
Added:
2 years ago